EZH2 and acute lymphoblastic leukemia: Leon et al. demonstrated that EZH2 loss-of-function mutations have increased sensitivity to CHK1 inhibitors caused by enhanced replication stress due to increased expression of MYC-N in T-ALL cells [132].